Jorgensen H, Lloret M, Lalayiannis A, Shroff R, Evenepoel P
Clin Kidney J. 2024; 17(5):sfae093.
PMID: 38817914
PMC: 11137676.
DOI: 10.1093/ckj/sfae093.
Padoan F, Guarnaroli M, Brugnara M, Piacentini G, Pietrobelli A, Pecoraro L
Biomedicines. 2024; 12(4).
PMID: 38672265
PMC: 11048674.
DOI: 10.3390/biomedicines12040911.
Hill Gallant K, Spiegel D
Curr Osteoporos Rep. 2017; 15(3):214-221.
PMID: 28474258
PMC: 5442193.
DOI: 10.1007/s11914-017-0368-x.
van der Velde R, Brouwers J, Geusens P, Lems W, van den Bergh J
Food Nutr Res. 2014; 58.
PMID: 25147494
PMC: 4126954.
DOI: 10.3402/fnr.v58.21796.
Anderson J, Klemmer P
Nutrients. 2013; 5(10):3964-74.
PMID: 24084054
PMC: 3820054.
DOI: 10.3390/nu5103964.
Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease.
Hill K, Martin B, Wastney M, McCabe G, Moe S, Weaver C
Kidney Int. 2012; 83(5):959-66.
PMID: 23254903
PMC: 4292921.
DOI: 10.1038/ki.2012.403.
Gestational urinary hyperthiosulfaturia protects hypercalciuric normal pregnant women from nephrolithiasis.
Yatzidis H
Int Urol Nephrol. 2005; 36(3):445-9.
PMID: 15783122
DOI: 10.1007/s11255-004-8784-0.
Jejunal absorption and secretion of calcium in patients with chronic renal disease on hemodialysis.
Parker T, HULL A, Pak C, Fordtran J
J Clin Invest. 1974; 54(2):358-65.
PMID: 4847249
PMC: 301563.
DOI: 10.1172/JCI107771.
Metabolism and action of the hormone vitamin D. Its relation to diseases of calcium homeostasis.
Coburn J, Hartenbower D, Norman A
West J Med. 1974; 121(1):22-44.
PMID: 4365934
PMC: 1129480.
Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.
Galceran T, Chan Y, Rapp N, Martin K, Slatopolsky E
J Clin Invest. 1986; 78(4):1097-102.
PMID: 3760186
PMC: 423770.
DOI: 10.1172/JCI112666.
I alpha-hydroxycholecalciferol: a treatment of renal bone disease.
Catto G, MacLeod M, PELC B, KODICEK E
Br Med J. 1975; 1(5948):12-4.
PMID: 1120218
PMC: 1671878.
DOI: 10.1136/bmj.1.5948.12-a.
Jejunal and ileal absorption in patients with chronic renal disease. Effect of 1alpha-hydroxycholecalciferol.
Parker T, Pak C, HULL A, DeLuca H, Fordtran J
J Clin Invest. 1976; 57(4):861-6.
PMID: 947957
PMC: 436729.
DOI: 10.1172/JCI108362.
Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog.
Rutherford W, BORDIER P, Marie P, Hruska K, Harter H, Greenwalt A
J Clin Invest. 1977; 60(2):332-41.
PMID: 874095
PMC: 372373.
DOI: 10.1172/JCI108781.
Renal bone disease.
Catto G
J R Coll Physicians Lond. 1976; 11(1):75-85.
PMID: 789876
PMC: 5368764.
Structural and functional adaptation after reduction of nephron population.
Finkelstein F, HAYSLETT J
Yale J Biol Med. 1979; 52(3):271-87.
PMID: 380185
PMC: 2595468.
